Medical Patent News

RSS

USPTO grants ISCO patent to International Stem Cell's hpSC

International Stem Cell Corporation, www.intlstemcell.com, announced today that the United States Patent and Trademark Office has granted ISCO patent number 7,732,202, the first of several pending patents relating to its development of human parthenogenetic Stem Cells. Human parthenogenetic stem cells are a new type of pluripotent stem cell that allows immune matching to potentially solve critical immune rejection problems, and does not involve the ethical issues that surround the use of fertilized human embryos.

8 Jun 2010

Clarient granted U.K. patent for TLE3 biomarker

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United Kingdom Patent Office has granted a U.K. patent on the Company's TLE3 biomarker, a marker which may be used to predict which cancer patients will respond favorably to taxane therapy.

8 Jun 2010

Dolcera releases new Patent Dashboard v1.1

Dolcera Corporation, a leading information services and technology firm that helps companies quickly and effectively navigate through their entire innovation cycle to achieve successful business outcomes, today announced its new Patent Dashboard, available for the first time as a standalone platform.

8 Jun 2010

US Court lifts stay on Cook's endovascular technology patent infringement case against Endologix

The United States District Court, Southern District of Indiana, has ruled in favor of Cook Incorporated in its decision to lift the stay on Cook's patent infringement case against Endologix, Inc.. With this ruling, the case, filed by Cook on October 6, 2009, will now proceed. The complaint claims infringement by Endologix of two Cook patents for endovascular technologies, one of Cook's leading technology portfolios.

8 Jun 2010

Lawsuit to be launched over breast cancer gene patent

BRCA1 and BRCA2 are two genes that have been identified to hold a key to women’s susceptibility to get breast or ovarian cancer. Changes also known as mutations in these genes are significant in women who go on to develop breast or ovarian cancer. Melbourne-based company Genetic Technologies Limited (GTL) has the exclusive license from American biotechnology company Myriad Genetics to carry out testing for the genes in Australia. Myriad holds a patent for these genes.

7 Jun 2010

CryoLife purchases patent involving formulation, use of recombinant human serum albumin and gluteraldehyde

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company whose products include BioGlue Surgical Adhesive, announced today that it has completed the purchase of U.S. patent # 6,329,337. The patent involves the formulation and use of recombinant human serum albumin and gluteraldehyde, and now becomes part of CryoLife's protein hydrogel patent portfolio, which includes BioGlue.

7 Jun 2010

The Female Health Company granted U.S. Patent for FC2 Female Condom

The Female Health Company today announced that on June 1, 2010, the U.S. Patent office issued patent number U.S. 7,726,316 B1 for its second generation product, the FC2 Female Condom. In addition to the newly issued U.S. patent, Spain, Greece and Turkey recently issued patents on the FC2 Female Condom.

7 Jun 2010

CytRx granted U.S. Patent for bafetinib

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the granting by the U.S. Patent and Trademark Office (USPTO) of U.S. Patent 7,728,131 for oncology drug candidate bafetinib, encompassing claims related to bafetinib's pharmaceutical compound and composition in all indications, as well as for use in methods for treating acute and chronic myelogenous leukemia and acute lymphoblastic leukemia.

7 Jun 2010

Biomoda granted Mexican patent for proprietary porphyrin-based compound

Cancer diagnostics company Biomoda, Inc. has been granted a Mexican patent for its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce red under ultraviolet light.

7 Jun 2010

Labopharm comments on the outcome of patent-infringement litigation related to Ultram ER

Labopharm Inc. today commented on the outcome of the appeal by Purdue Pharma Products L.P. and the cross-appeal by Par Pharmaceutical Companies, Inc. of the decision of the United States District Court for the District of Delaware in August 2009 on patent-infringement litigation initiated by Purdue against Par relating to Ultram ER (tramadol hydrochloride extended-release tablets).

4 Jun 2010

USPTO decision confirms validity of Haemonetics' '983 Patent

Haemonetics Corporation announced today that on May 28, 2010, the United States Patent and Trademark Office issued a decision confirming the validity of Haemonetics' '983 Patent in light of numerous prior art references cited by Fenwal Inc. As such, the USPTO explicitly rejected Fenwal's position that the Patent was invalid over the prior art.

4 Jun 2010

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Intellect Neurosciences, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent related to the Company's humanized monoclonal antibody, IN-N01, being developed as a disease-modifying treatment for Alzheimer's disease and other related indications.

4 Jun 2010

Amedica secures US patent for novel hip implant

Amedica Corporation, a spinal and orthopaedic implant and instrument manufacturer focused on unique silicon nitride (SiN) ceramic technologies, announced today that it has been granted United States Patent No. 7,695,521 covering its novel hip implant featuring a monoblock ceramic acetabular cup for use in articulating joints for total joint replacement.

3 Jun 2010

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

2 Jun 2010

Generex awarded new patents in Japan and Ukraine for buccal drug delivery platform technologies

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has been awarded two new patents in Japan and Ukraine.

2 Jun 2010

AMS issued U.S. patent covering surgical methodology for implanting AdVance Male Sling

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, announced today that the United States Patent and Trademark Office has issued U.S. Patent Number 7,686,760 covering the surgical methodology for implanting the AMS AdVance® Male Sling. This patent provides AMS with broad patent coverage on transobturator surgical procedures to treat male incontinence.

29 May 2010

Shire receives Paragraph IV Notice Letter from Zydus over filing of ANDA for generic LIALDA

Shire plc, the global specialty biopharmaceutical company, announces that it has received a Paragraph IV Notice Letter today from Zydus Pharmaceuticals USA, Inc. advising of the filing of an Abbreviated New Drug Application ("ANDA") for a generic version of Shire's 1.2g mesalamine delayed release tablets, LIALDA(R).

29 May 2010

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.

28 May 2010

US District Court dismisses all claims and counterclaims in thalidomide patent cases

Celgene Corporation announced that as a result of Barr Laboratories, Inc., withdrawing its Abbreviated New Drug Application (ANDA) for thalidomide with the US Food and Drug Administration, the US District Court for the District of New Jersey has granted the requested dismissal of all claims and counterclaims in the thalidomide patent cases.

27 May 2010

Amira announces UK patent grant for heteroalkyl antagonists of prostaglandin D2 receptors

Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2461629, titled, "HETEROALKYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS," which includes coverage of Amira's AM461 DP2 receptor antagonist.

27 May 2010

Medical Patent News

USPTO grants ISCO patent to International Stem Cell's hpSC

Clarient granted U.K. patent for TLE3 biomarker

Dolcera releases new Patent Dashboard v1.1

US Court lifts stay on Cook's endovascular technology patent infringement case against Endologix

Lawsuit to be launched over breast cancer gene patent

CryoLife purchases patent involving formulation, use of recombinant human serum albumin and gluteraldehyde

The Female Health Company granted U.S. Patent for FC2 Female Condom

CytRx granted U.S. Patent for bafetinib

Biomoda granted Mexican patent for proprietary porphyrin-based compound

Labopharm comments on the outcome of patent-infringement litigation related to Ultram ER

USPTO decision confirms validity of Haemonetics' '983 Patent

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Amedica secures US patent for novel hip implant

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Generex awarded new patents in Japan and Ukraine for buccal drug delivery platform technologies

AMS issued U.S. patent covering surgical methodology for implanting AdVance Male Sling

Shire receives Paragraph IV Notice Letter from Zydus over filing of ANDA for generic LIALDA

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

US District Court dismisses all claims and counterclaims in thalidomide patent cases

Amira announces UK patent grant for heteroalkyl antagonists of prostaglandin D2 receptors

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Latest News